Harmony Biosciences Holdings, Inc.
A biopharmaceutical company in Plymouth Meeting, Pennsylvania, that makes WAKIX (pitolisant), a medication for narcolepsy that helps people with the sleep disorder stay awake and controls sudden muscle weakness (cataplexy). Founded in 2017 by Paragon Biosciences, the company licensed the drug's U.S. rights from the French firm Bioprojet. The brand name WAKIX is a play on the word "wake," and unlike many narcolepsy treatments, it is not a controlled substance.
Sold 4.60M
Sold 4.60M
Granted 44.5K
Granted 192.3K · Sold 103.5K
Granted 73.3K · Sold 45.2K
Granted 7.5K
Granted 7.6K
Granted 199.1K · Sold 174.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Marshman Fund Trust II10% owner · 2 transactions | -43.2% | 6.05Mas of Nov 2024 | — | — | 4.60M |
| Gracias Antonio J. +8 co-filersDirector, 10% owner, 10% owner · 3 transactions | — | 579.5K | — | — | 4.60M |
| Budur KumarCHIEF MEDICAL OFFICER · 10 transactions | — | 33.0K | 44.5K | — | — |
| Kapadia SandipCHIEF FINANCIAL OFFICER · 25 transactions | -18.3% | 24.5K | 192.3K | — | 103.5K |
| Dayno Jeffrey M.PRESIDENT, CEO, Director · 11 transactions | — | 13.0K | 73.3K | — | 45.2K |
| Zaeske Adam H.CHIEF COMMERCIAL OFFICER · 2 transactions | — | 4.3K | 7.5K | — | — |
| Serafin AndrewCHIEF STRATEGY OFFICER · 6 transactions | +60.2% | 1.5K | 7.6K | — | — |
| Dierks JeffreyCHIEF COMMERCIAL OFFICER · 33 transactions | -82.1% | 500as of Mar 2025 | 199.1K | — | 174.4K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -9.52M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.